News

Zenas BioPharma Unveils Participation in Key Investor Events

Zenas BioPharma Unveils Participation in Key Investor Events

Zenas BioPharma Engages with Investors at Upcoming Conferences

WALTHAM, Mass – Zenas BioPharma, Inc. (Nasdaq: ZBIO) is excited to announce its participation in a series of notable healthcare investor conferences. As a clinical-stage biopharmaceutical company, Zenas is dedicated to developing transformative therapies that primarily focus on immunology, and these events present a valuable opportunity to connect with investors and share insights on our progress.

Healthcare Investor Conference Schedule

Participating conferences include:

Healthcare Innovation Conference

The first event on the calendar is Guggenheim’s inaugural Healthcare Innovation Conference. This conference is set to happen soon, allowing the Zenas team to engage with industry professionals and investors alike.

International Presence at Jefferies London Healthcare Conference

Another significant venue will be the Jefferies London Healthcare Conference, where Zenas will present crucial information about its innovations and strategies on a global stage, enhancing its visibility among European investors.

Citi’s Global Healthcare Conference

Next, Zenas will take part in Citi’s 2024 Global Healthcare Conference. This global conference will allow the company to showcase its advancements and plans directly to a wide audience of healthcare specialists and potential investors.

HealthCONx Conference Insights

Lastly, Zenas will appear at the Evercore ISI HealthCONx Conference. Each presentation will provide listeners with an in-depth look at Zenas' strategic direction, emphasizing how the company aims to be a front-runner in developing innovative therapies for autoimmune diseases.

Webcasts and Presentations

For those unable to attend in person, live webcasts and archived presentations will be accessible. Interested parties can find these resources in the Events and Presentations section of the Zenas BioPharma website.

About Zenas BioPharma, Inc.

As a clinical-stage global biopharmaceutical company, Zenas BioPharma is committed to making significant strides in immunology-based therapies aimed at improving the quality of life for patients. Zenas prides itself on its experienced leadership and an effective product acquisition strategy that drives innovation in treating autoimmune diseases.

Leading Product Candidate

The company’s lead product candidate, obexelimab, stands out as a bifunctional monoclonal antibody targeting both CD19 and Fc?RIIb. This innovative drug is designed to inhibit the activity of pathogenic B cells while preserving the overall immune system functionality, representing a significant advancement in the treatment of chronic autoimmune conditions.

Global Impact and Commitment

Zenas BioPharma envisions addressing the clinical needs of patients living with autoimmune diseases through cutting-edge science and dedicated research. With a strong focus on product development and a clear pathway to commercialization, Zenas is arming itself with the tools necessary to revolutionize patient care.

Investor Contact Information

If you would like to reach out to Zenas regarding investment opportunities, please contact:

Matthew Osborne
Investor Relations and Corporate Communications
Email:
Matt.osborne@zenasbio.com

Frequently Asked Questions

What type of company is Zenas BioPharma?

Zenas BioPharma is a clinical-stage global biopharmaceutical company focused on developing immunology-based therapies.

Where will Zenas be presenting its information?

Zenas will be participating in multiple healthcare investor conferences, including those hosted by Guggenheim and Jefferies.

What is obexelimab?

Obexelimab is Zenas’ lead product candidate, designed to treat autoimmune diseases without depleting B cells in the immune system.

How can I access Zenas' presentations?

Live webcasts and archived recordings of Zenas’ presentations will be available in the Events and Presentations section of their website.

Who can I contact for investor inquiries?

For investor relations, please contact Matthew Osborne via email at Matt.osborne@zenasbio.com.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Truss Financial Tackles Home Equity Closing Delays

Updated Category News Views 8

Truss Financial Group's Bold Move Against Closing Delays In real estate, time is money. Even the most casual market observer could tell you delays can slice through a deal like a hot knife through butter. That's the headache home equity borrowers face, blindsided by closing delays that sneak up on them without warning. An Industry Bottleneck Finally Addressed Enter Truss...

Continue Reading
Community Banks Missing $106B Lending Opportunity?

Updated Category News Views 6

A Missed Opportunity for Community Banks It's a classic tale: community banks sleepwalking while big players snatch up low-hanging fruit right in their own backyards. According to the latest report by Cornerstone Advisors, commissioned by Teslar Software, these banks are essentially leaving $106 billion on the table when it comes to consumer lending. That's not just chump...

Continue Reading
Dentistry.One Achieves HITRUST i1, Boosts Cybertrust

Updated Category News Views 3

HITRUST i1 Certification: The Gold Standard in Security For a world increasingly reliant on digital infrastructure, cybersecurity certification is no longer just a badge of honor; it's a cornerstone of trust. Dentistry.One nailed this down by bagging that coveted HITRUST i1 certification. When folks talk about securing data, HITRUST might as well be speaking gospel. We're...

Continue Reading
Charter Next Generation Unveils Gen 2 MDO-PE Films

Updated Category News Views 7

Peering Into CNG's Latest Innovation Charter Next Generation (CNG) just threw down a hefty gauntlet with its launch of next-gen machine-direction-oriented polyethylene (MDO-PE) solutions. They're pushing the envelope on what recycle-ready packaging can do, folks. Let's not mince words—other players in the field better have their game faces on. This ain't just another...

Continue Reading
Cala Launches Game-Changer Wearable for Tremor Relief

Updated Category News Views 10

Breaking New Ground in Neuromodulation Medical tech's on a roll, and Cala Health just hopped on the fast track with their latest launch—the Cala kIQ Plus System. This bad boy is aiming to offer relief for those grappling with hand tremors, thanks to its FDA clearance and a host of new features. It's the first of its kind, combining multiple therapy modes with an...

Continue Reading
Epic Political Thriller Explores Humanity's Future

Updated Category News Views 4

Adams' Provocative Debut Asks Timeless Questions Sometimes life throws a philosophical curveball, and that's exactly what John C. Adams has done with his debut novel, The Third Phase. This isn't your average political yarn—it's an intricate tapestry intertwining political intrigue, deep spiritual inquiry, and hearty doses of classic philosophy. A Whirlwind Journey...

Continue Reading
ROKFORM’s Signal Card: A Wallet Tracker for All

Updated Category News Views 7

The Gadget You Didn't Know You Needed Ever feel that momentary panic when your wallet seems to have vanished into thin air? ROKFORM's fresh offering, the Signal Card, tackles that heart-stopping moment head-on. They've taken the mundane act of misplacing your wallet and transformed it with their sleek, credit-card-sized tracker. This baby pairs seamlessly with Apple Find...

Continue Reading
Navigating Holiday Sweets: Healthy Balancing Acts

Updated Category News Views 6

In the middle of the sweet madness that is the holiday season, Crispy Green and Dr. Nicole Avena are playing guide to families drowning in sugar. This isn't just a once-a-year Halloween headache; we're starting that sugar spiral early and letting it ride until the New Year approaches. It's an all-hands-on-deck situation if families want to dodge that sugar overload. Why...

Continue Reading
Cure Blindness Project's 770K Screenings for World Sight Day

Updated Category News Views 5

Visionary Steps Toward a Brighter Future No two words could describe the task that Cure Blindness Project is tackling this year: vision and action. Marking World Sight Day on October 8, they plan to usher in 770,000 eye screenings across Asia, Africa, and the Caribbean. These initiatives aren't just numbers—they're a colossal step toward lifting the veil of avoidable...

Continue Reading
NYSE Texas Redefines the U.S. Capital Markets Landscape

Updated Category News Views 10

NYSE Texas: Carving a Niche The notion of 'Y'all Street' might seem like a gimmick, but NYSE Texas is pushing a serious agenda with its newly released white paper, 'NYSE Texas and the Reshaping of U.S. Capital Markets.' This is no small feat. Texas is already housing 235 NYSE-listed companies, boasting a colossal combined worth of $4.8 trillion. With 130 of these firms...

Continue Reading

Top 5 Most Recently Viewed Articles

Esperion Partners with Dr. Reddy's to Protect NEXLETOL® and NEXLIZET®

Updated Category News Views 185

Esperion's Strategic Settlement with Dr. Reddy’s Laboratories Esperion (NASDAQ: ESPR) has recently solidified its position in the competitive biopharmaceutical market with a pivotal agreement with Dr. Reddy’s Laboratories, Inc. This partnership marks a crucial step in the ongoing efforts to protect the company’s flagship products, NEXLETOL® (bempedoic acid) and...

Continue Reading
Marshall Group's Continued Success in the Audio Industry

Updated Category News Views 113

Marshall Group Reports Impressive Growth Marshall Group has continued its impressive growth into the second quarter of 2024, achieving a notable 15% increase in net sales, totaling SEK 1,097.5 million. Additionally, the adjusted operating profit rose significantly to SEK 242.1 million, resulting in an impressive adjusted operating margin of 22.1%. Building on a Strong...

Continue Reading
Godawan Artisanal Indian Single Malt Arrives in the UK

Updated Category News Views 439

Godawan Artisanal Indian Single Malt Makes Its UK Debut Recently, an exciting milestone was reached with the launch of Godawan Artisanal Indian Single Malt in the UK. This premium whisky, crafted by Diageo India, has captured hearts and palates worldwide. With two distinctive expressions, Rich & Rounded and Fruit & Spice, Godawan is all set to tantalize whisky enthusiasts...

Continue Reading
China's Strategic Response to US Tariff Increases Affects Companies

Updated Category News Views 327

China's Response to Increased US Tariffs China has taken a strong stand against recent tariff increases implemented by the U.S., positioning itself as a formidable player in international trade. This reaction includes reciprocal tariffs on a range of American products, sanctions on U.S. companies, and plans to address these issues through the World Trade Organization....

Continue Reading
Infosys and AGCO Join Forces for Transformational Success

Updated Category News Views 190

Infosys and AGCO Team Up for IT and HR Transformation Building on a longstanding relationship to enhance AGCO's operational framework for growth by leveraging Infosys Cobalt and Infosys Topaz. Infosys (NSE: INFY), a global leader in next-generation digital services and consulting, has announced the continuation of its strategic partnership with AGCO Corporation (NYSE:...

Continue Reading